Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
other
Intercell’s Japanese Encephalitis vaccine safe in Phase III trials

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
12.01.2006
Intercell AG (VSE, "ICLL") announced today the achievement of an
important milestone in the progress of its international,
multi-center Phase III clinical trial program of its Japanese
Encephalitis vaccine:
An independent Data and Safety Monitoring Board (DSMB), consisting of
two European and one US expert from the field of Clinical
Pharmacology and Vaccinology, has reviewed and evaluated the safety
data from the first proportion of subjects vaccinated in the Phase
III trial. After discussion of all safety data provided to the board
members, the DSMB unanimously concluded that no safety concerns have
been observed. From these preliminary results, the safety assessment
is favorable which supports the ongoing rapid recruitment of
approximately 5,000 subjects in the entire Phase III program.
Completion of recruitment for the pivotal safety and the pivotal
immunogenicity trial is expected early this year.
Results of these Phase III trials are expected in mid 2006. First
license applications will be made in the US, EU and Australia.
About Intercell’s JE vaccine
Intercell´s novel Japanese Encephalitis vaccine is a purified,
inactivated vaccine for active immunization of adults against the
Japanese Encephalitis virus and has successfully concluded Phase II
clinical trials.
In the Phase II head-to-head comparison with JE-VAX®, Intercell’s
vaccine was shown to be: » Less reactogenic - both in frequency and
intensity » More potent - higher antibody levels at all doses studied
one month after   the immunizations; this vaccine also showed high
seroconversion rates one   month after a single dose » More
convenient - 2 doses versus 3 doses and liquid versus freeze-dried
format » More persistent - higher persistence of antibodies two years
after primary   immunization
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
end of announcement                               euro adhoc 12.01.2006 17:36:07

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG